Show simple item record

dc.contributor.authorWang, Feng
dc.contributor.authorGiskeødegård, Guro F.
dc.contributor.authorSkarra, Sissel
dc.contributor.authorEngstrøm, Monica Jernberg
dc.contributor.authorHagen, Lars
dc.contributor.authorGeisler, Jürgen
dc.contributor.authorMikkola, Tomi S.
dc.contributor.authorTikkanen, Matti J.
dc.contributor.authorDebik, Julia
dc.contributor.authorReidunsdatter, Randi Johansen
dc.contributor.authorBathen, Tone Frost
dc.identifier.citationClinical and Experimental Medicine. 2023, 23 (7), 3883-3893.en_US
dc.description.abstractMetabolic reprogramming in breast cancer involves changes in steroid hormone synthesis and metabolism. Alterations in estrogen levels in both breast tissue and blood may influence carcinogenesis, breast cancer growth, and response to therapy. Our aim was to examine whether serum steroid hormone concentrations could predict the risk of recurrence and treatment-related fatigue in patients with breast cancer. This study included 66 postmenopausal patients with estrogen receptor-positive breast cancer who underwent surgery, radiotherapy, and adjuvant endocrine treatment. Serum samples were collected at six different time points [before the start of radiotherapy (as baseline), immediately after radiotherapy, and then 3, 6, 12 months, and 7–12 years after radiotherapy]. Serum concentrations of eight steroid hormones (cortisol, cortisone, 17α-hydroxyprogesterone, 17β-estradiol, estrone, androstenedione, testosterone, and progesterone) were measured using a liquid chromatography–tandem mass spectrometry-based method. Breast cancer recurrence was defined as clinically proven relapse/metastatic breast cancer or breast cancer-related death. Fatigue was assessed with the QLQ-C30 questionnaire. Serum steroid hormone concentrations measured before and immediately after radiotherapy differed between relapse and relapse-free patients [(accuracy 68.1%, p  = 0.02, and 63.2%, p  = 0.03, respectively, partial least squares discriminant analysis (PLS-DA)]. Baseline cortisol levels were lower in patients who relapsed than in those who did not (p < 0.05). The Kaplan–Meier analysis showed that patients with high baseline concentrations of cortisol (≥ median) had a significantly lower risk of breast cancer recurrence than patients with low cortisol levels (<median) (p  = 0.02). During follow-up, there was a decrease in cortisol and cortisone concentrations in relapse-free patients, whereas these steroid hormones increased in patients who relapsed. In addition, steroid hormone concentrations immediately after radiotherapy were associated with treatment-related fatigue (accuracy of 62.7%, p  = 0.03, PLS-DA). However, baseline steroid hormone levels did not predict fatigue at 1 year or at 7–12 years. In conclusion, breast cancer patients with low baseline cortisol levels were more likely to experience recurrence. During follow-up, cortisol and cortisone levels decreased in relapse-free patients but increased in patients with recurrence. Thus, cortisol and cortisone may act as potential biomarkers indicating individual risk of recurrence.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleAssociation of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast canceren_US
dc.title.alternativeAssociation of serum cortisol and cortisone levels and risk of recurrence after endocrine treatment in breast canceren_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalClinical and Experimental Medicineen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse 4.0 Internasjonal